Virtu Financial LLC Makes New $674,000 Investment in Altimmune, Inc. (NASDAQ:ALT)

Virtu Financial LLC bought a new stake in shares of Altimmune, Inc. (NASDAQ:ALT - Free Report) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund bought 109,759 shares of the company's stock, valued at approximately $674,000. Virtu Financial LLC owned 0.15% of Altimmune as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of ALT. Price T Rowe Associates Inc. MD raised its position in shares of Altimmune by 13.6% during the first quarter. Price T Rowe Associates Inc. MD now owns 15,238 shares of the company's stock worth $156,000 after purchasing an additional 1,821 shares during the period. California State Teachers Retirement System raised its holdings in Altimmune by 517.7% during the first quarter. California State Teachers Retirement System now owns 53,730 shares of the company's stock worth $547,000 after buying an additional 45,032 shares during the last quarter. Hennion & Walsh Asset Management Inc. bought a new position in shares of Altimmune in the second quarter valued at $860,000. Horizon Wealth Management LLC acquired a new position in shares of Altimmune during the second quarter valued at about $66,000. Finally, Bank of New York Mellon Corp increased its position in shares of Altimmune by 28.6% during the second quarter. Bank of New York Mellon Corp now owns 243,808 shares of the company's stock worth $1,621,000 after acquiring an additional 54,154 shares in the last quarter. 78.05% of the stock is owned by institutional investors.

Altimmune Stock Performance

Altimmune stock traded up $0.44 during midday trading on Friday, reaching $9.03. 3,005,469 shares of the stock were exchanged, compared to its average volume of 3,839,838. Altimmune, Inc. has a 52 week low of $5.28 and a 52 week high of $14.84. The firm has a market cap of $642.26 million, a PE ratio of -5.83 and a beta of 0.15. The company's fifty day moving average is $7.71 and its 200-day moving average is $7.06.

Altimmune (NASDAQ:ALT - Get Free Report) last announced its earnings results on Tuesday, November 12th. The company reported ($0.32) earnings per share for the quarter, beating analysts' consensus estimates of ($0.35) by $0.03. The business had revenue of $0.01 million for the quarter. Altimmune had a negative net margin of 199,076.92% and a negative return on equity of 55.81%. During the same period in the prior year, the business earned ($0.39) earnings per share. On average, sell-side analysts anticipate that Altimmune, Inc. will post -1.36 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on ALT shares. UBS Group assumed coverage on shares of Altimmune in a research note on Tuesday, November 12th. They issued a "buy" rating and a $26.00 target price for the company. HC Wainwright reaffirmed a "buy" rating and set a $12.00 price target on shares of Altimmune in a research report on Thursday, November 14th. Two investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Altimmune presently has a consensus rating of "Moderate Buy" and an average target price of $20.00.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.